These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9777790)

  • 21. Tazarotene-loaded
    Erol İ; Üstündağ Okur N; Orak D; Sipahi H; Aydın A; Özer Ö
    Pharm Dev Technol; 2020 Oct; 25(8):909-918. PubMed ID: 32364036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing treatment with topical tazarotene.
    Guenther LC
    Am J Clin Dermatol; 2003; 4(3):197-202. PubMed ID: 12627995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid.
    Lebwohl M
    J Am Acad Dermatol; 2000 Aug; 43(2 Pt 3):S43-6. PubMed ID: 10898829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The link between autophagy and psoriasis.
    Liang N; Zhang K
    Acta Histochem; 2024 May; 126(4):152166. PubMed ID: 38688157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reciprocal altered expression of T-cadherin and P-cadherin in psoriasis vulgaris.
    Zhou S; Matsuyoshi N; Takeuchi T; Ohtsuki Y; Miyachi Y
    Br J Dermatol; 2003 Aug; 149(2):268-73. PubMed ID: 12932231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative study of histopathological and immunohistochemical findings in skin biopsies from patients with psoriasis before and after treatment with acitretin.
    Werner B; Bresch M; Brenner FM; Lima HC
    J Cutan Pathol; 2008 Mar; 35(3):302-10. PubMed ID: 18251745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis.
    Lebwohl M; Ast E; Callen JP; Cullen SI; Hong SR; Kulp-Shorten CL; Lowe NJ; Phillips TJ; Rosen T; Wolf DI; Quell JM; Sefton J; Lue JC; Gibson JR; Chandraratna RA
    J Am Acad Dermatol; 1998 May; 38(5 Pt 1):705-11. PubMed ID: 9591815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic profile of tazarotene.
    Duvic M
    Cutis; 1998 Feb; 61(2 Suppl):22-6. PubMed ID: 9787988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and safety of tazarotene.
    Menter A
    J Am Acad Dermatol; 2000 Aug; 43(2 Pt 3):S31-5. PubMed ID: 10898827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Inhibition of promyelocytic leukemia gene by tazarotene in hyperproliferative epidermis of psoriasis].
    Wang QY; Yan HL; Liu P; Peng ZH; Tan SS
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1146-8. PubMed ID: 16939905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered expression of keratinocyte growth factor and its receptor in psoriasis.
    Finch PW; Murphy F; Cardinale I; Krueger JG
    Am J Pathol; 1997 Dec; 151(6):1619-28. PubMed ID: 9403712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder.
    Li AG; Wang D; Feng XH; Wang XJ
    EMBO J; 2004 Apr; 23(8):1770-81. PubMed ID: 15057277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upregulation of ANGPTL6 in mouse keratinocytes enhances susceptibility to psoriasis.
    Tanigawa H; Miyata K; Tian Z; Aoi J; Kadomatsu T; Fukushima S; Ogata A; Takeda N; Zhao J; Zhu S; Terada K; Endo M; Morinaga J; Sugizaki T; Sato M; Morioka MS; Manabe I; Mashimo Y; Hata A; Taketomi Y; Yamamoto K; Murakami M; Araki K; Jinnin M; Ihn H; Oike Y
    Sci Rep; 2016 Oct; 6():34690. PubMed ID: 27698489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis.
    Tang-Liu DD; Matsumoto RM; Usansky JI
    Clin Pharmacokinet; 1999 Oct; 37(4):273-87. PubMed ID: 10554045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes.
    Piepkorn M; Predd H; Underwood R; Cook P
    Arch Dermatol Res; 2003 Jul; 295(3):93-101. PubMed ID: 12768307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tazarotene combination treatments in psoriasis.
    Guenther L
    J Am Acad Dermatol; 2000 Aug; 43(2 Pt 3):S36-42. PubMed ID: 10898828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimising the use of tazarotene in clinical practice: consensus statement from the European advisory panel for tazarotene (Zorac TM).
    Gollnick HP; Finzi AF; Marks R; Barker JN; Jansen C; Revuz J; Saurat J
    Dermatology; 1999; 199(1):40-6. PubMed ID: 10449956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis.
    Weinstein GD
    Br J Dermatol; 1996 Oct; 135 Suppl 49():32-6. PubMed ID: 9035703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Receptor-selective retinoids for psoriasis: focus on tazarotene.
    Weindl G; Roeder A; Schäfer-Korting M; Schaller M; Korting HC
    Am J Clin Dermatol; 2006; 7(2):85-97. PubMed ID: 16605289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis.
    Schaper K; Dickhaut J; Japtok L; Kietzmann M; Mischke R; Kleuser B; Bäumer W
    J Dermatol Sci; 2013 Jul; 71(1):29-36. PubMed ID: 23643308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.